ライフサイエンスコーパス: lymph node metastases

1 Positive SNs were detected in 1 patient with lymph node metastases.

2 nomogram to estimate the individual risk of lymph node metastases.

3 transitional cells may be the source of the lymph node metastases.

4 that correlates with increased frequency of lymph node metastases.

5 s should respect the presented topography of lymph node metastases.

6 s) after a previous clearance of more than 5 lymph node metastases.

7 y, including some patients with common iliac lymph node metastases.

8 more tumor cells inside lymphatics, and more lymph node metastases.

9 rimary tumors, along with liver and draining lymph node metastases.

10 both with (P = 0.006) and without (P = 0.03) lymph node metastases.

11 in situ, and general loss of Nuc-pYStat5 in lymph node metastases.

12 ease or higher and, especially, locoregional lymph node metastases.

13 s as a result of local invasion and regional lymph node metastases.

14 stic variables than tumor stage or number of lymph node metastases.

15 ocarcinoma (EAC) given the low likelihood of lymph node metastases.

16 or cell nuclei in various gastric tumors and lymph node metastases.

17 t carcinomas and is associated with axillary lymph node metastases.

18 omarker and therapeutic target in ESCCs with lymph node metastases.

19 nd prognosis of melanoma patients with early lymph node metastases.

20 emalignant lesions (PPOLS) to malignancy and lymph node metastases.

21 ns, including 55 primary tumors and 9 pelvic lymph node metastases.

22 minin 5 gamma 2 chain domain III fragment in lymph node metastases.

23 observed in distant organs in the absence of lymph node metastases.

24 -fold) but also the fraction of animals with lymph node metastases.

25 CIS), 18 invasive breast carcinomas, and two lymph node metastases.

26 s recovered from breast cancer patients with lymph node metastases.

27 f which were associated with the presence of lymph node metastases.

28 mor burden, as well as decreases in regional lymph node metastases.

29 an also make it difficult to detect axillary lymph node metastases.

30 anase expression is associated with sentinel lymph node metastases.

31 t invasive cancer at the margin, and 54% had lymph node metastases.

32 ee subtypes, one of which also included most lymph node metastases.

33 cinomas, in the lymphovascular space, and in lymph node metastases.

34 n of these genes in malignant cell lines and lymph node metastases.

35 only in invasive breast carcinomas and their lymph node metastases.

36 -M expression, and a propensity for regional lymph node metastases.

37 cluster in malignant prostate cell lines and lymph node metastases.

38 tumor showed a decrease in the corresponding lymph node metastases.

39 supraclavicular region is a common site for lymph node metastases.

40 erate to poor histologic grade, and positive lymph node metastases.

41 h disease progression and a higher number of lymph node metastases.

42 ive, early-stage breast cancer without overt lymph node metastases.

43 abolism between the primary PDTX and distant lymph node metastases.

44 tion patterns in primary PC foci and matched lymph node metastases.

45 1 PCa patient with proven iliac and inguinal lymph node metastases.

46 that fatal, distant metastases are seeded by lymph node metastases.

47 ing five matched pairs of primary tumors and lymph node metastases.

48 recurrences have a higher risk for lung and lymph node metastases.

49 , but had fewer (2.9%, versus 16.7% in DGCs) lymph node metastases.

50 than age 45 years does not include cervical lymph node metastases.

51 lumes of interest in all visually detectable lymph node metastases.

52 e metastases and better for the detection of lymph node metastases.

53 pared with normal tissues, primary tumors or lymph node metastases.

54 (TNBC) cells, both in primary tumors and in lymph node metastases.

55 ted between primary tumors and corresponding lymph node metastases.

56 ronment, leading to widespread pulmonary and lymph-node metastases.

57 nsion and positive surgical margins, but not lymph-node metastases.

58 aging modality or technique for diagnosis of lymph-node metastases.

59 imaging for assessment of tumor margins and (lymph node) metastases.

60 sion or (ii) extrahepatic (adrenal/bone/lung/lymph node) metastases.

61 erns were observed for mean (SD) nonsentinel lymph node metastases: 0.48 (1.30) for no ENE vs 1.91 (2

62 Thirty-five patients had lymph node metastases, 19 only in the SLN.

63 patients with melanoma with palpable, proven lymph node metastases (2003-2008) referred for examinati

64 metrial invasion (20 mL) and the presence of lymph node metastases (30 mL) yielded odds ratios of 7.8

65 common iliac (6/16, 38%) and internal iliac lymph node metastases (6/16, 38%).

66 common iliac (6/16, 38%) and internal iliac lymph node metastases (6/16, 38%).

67 hout lymph node metastases versus those with lymph node metastases (78% versus 48%, P = 0.0137).

68 As lymph node metastases accurately predict poor disease ou

69 Lymph node metastases affect management and prognosis of

70 ast pCR and 100% had no evidence of axillary lymph node metastases after NCT.

71 ncorporate distribution as well as number of lymph node metastases after preoperative chemoradiothera

72 ary prostate cancer and confirmed absence of lymph node metastases (after lymph node dissection) were

73 tients after complete dissection of regional lymph node metastases (AJCC stage III), with 28 of 55 pa

74 Relatively distant lymph node metastases along the celiac axis and/or the p

75 A proportion will present or recur with lymph node metastases (American Joint Committee on Cance

76 involved was two for patients with proximal lymph node metastases and 1.5 for patients with mesorect

77 airs from 13 HNSCC patients with synchronous lymph node metastases and 10 patients with metachronous

78 d as benign 6 of 11 lesions considered to be lymph node metastases and 11 of 15 lesions considered to

79 260 esophageal cancers, including 40 matched lymph node metastases and 137 normal adjacent esophageal

80 ide and cisplatin for pulmonary and thoracic lymph node metastases and a rising serum alpha-fetoprote

81 vels of the four HOX clusters were examined, lymph node metastases and cell lines derived from lymph

82 f mortality when diagnosed in the absence of lymph node metastases and distant metastases, as shown e

83 with 5-aza also prevented the development of lymph node metastases and dramatically extended survival

84 ignificantly associated with the presence of lymph node metastases and invasive tumor stages.

85 Patients with small lymph node metastases and local recurrence were not excl

86 ation is based on number and not location of lymph node metastases and may understage disease after c

87 Lymph node metastases and not pathologic response to che

88 e the association of OS with the presence of lymph node metastases and number of metastatic nodes.

89 an increased risk of submucosal invasion and lymph node metastases and should be factored into the de

90 ensive disease (extrathyroidal extension and lymph node metastases) and those who are more likely to

91 erexpressed in 35% of primary tumors, 30% of lymph node metastases, and 70% of recurrences in contras

92 be associated with extrathyroidal extension, lymph node metastases, and advanced stage in two meta-an

93 -DCFPyL and (18)F-PSMA-1007 for local tumor, lymph node metastases, and bone metastases.

94 o primary tumor size, location, frequency of lymph node metastases, and disease-specific and disease-

95 cal aggressiveness (triple-negative cancers, lymph node metastases, and distant metastases) of small-

96 igher grade tumor, an increased incidence of lymph node metastases, and elevated risk of distant recu

97 ted to deep myometrial invasion, presence of lymph node metastases, and high histologic grade (P < 0.

98 regional (P = 0.002) and distant (P = 0.012) lymph node metastases, and higher relapse rate (P < 0.00

99 r prostate bed after radical prostatectomy), lymph node metastases, and other metastases.

100 ologic grade, tumor hormone receptor status, lymph node metastases, and patient age and condition at

101 Total RNA from 21 ILCs, 38 IDCs, two lymph node metastases, and three normal tissues were amp

102 , extent, and type of an invasive component, lymph node metastases, and vascular invasion.

103 on than does unenhanced MRI for detection of lymph-node metastases, and allows functional and anatomi

104 a significant increase in the prevalence of lymph node metastases,and there is no "safe" level of in

105 Our results suggest that cervical lymph node metastases are associated with compromised su

106 Lateral lymph node metastases are associated with locoregional r

107 retrospective studies suggest that regional lymph node metastases are associated with tumor recurren

108 technologies for the clinical assessment of lymph node metastases are based on the detection of canc

109 0 (N1), 11 to 20 (N2), and more than 20 (N3) lymph node metastases are important prognostic classifie

110 A systematic review has shown that lymph node metastases are rare ( approximately 2%) with

111 Cervical lymph node metastases are recognized as a prognostic ind

112 um levels required for efficient blockade of lymph node metastases are strictly dependent on the VEGF

113 Lymph node metastases are the most significant prognosti

114 d observational analyses suggest that occult lymph-node metastases are an important prognostic factor

115 Treatment after the formation of lymph node metastases arrests the metastatic process wit

116 Increased levels of EPO and EPOR in lymph node metastases as compared to primary tumors from

117 ijacked by cancer cells to establish initial lymph node metastases, as well as by infectious agents a

118 nuclear level of DNAJB6 and the presence of lymph node metastases at diagnosis could be used to stra

119 history of bilateral orchiectomies, regional lymph node metastases at diagnosis, prior prostatectomy,

120 reast is correlated with absence of axillary lymph node metastases at final pathology (ypN0) in patie

121 n level before reoperation and the number of lymph node metastases at reoperation and biochemical cur

122 Patients with lymph node metastases at the time of diagnosis had an in

123 st cancers and 100% in breast cancer derived lymph node metastases attracted special attention.

124 ration depth correlates with the rate of the lymph node metastases, but a clear watershed between dee

125 igh sensitivity and specificity in depicting lymph node metastases, but guidelines have not yet been

126 1% to 3% reduction in recurrence of axillary lymph node metastases, but is associated with a 14% risk

127 scriptional cluster, including cutaneous and lymph node metastases, but not the type II cluster, not

128 patients with oral cancer and no evidence of lymph node metastases by clinical examination or CT/MRI

129 cell-based immunotherapies, to: (i) prevent lymph node metastases by redistributing cytotoxic NK cel

130 platin-based chemotherapy, and it eliminated lymph node metastases by targeting CSCs and the tumor bu

131 e, SPECT/CT allowed the identification of 11 lymph node metastases classified as thyroid remnant or a

132 d that TGLI1, but not GLI1, was increased in lymph node metastases compared to matched primary tumors

133 ificantly higher Sec62 levels in tumors with lymph node metastases compared with nonmetastatic tumors

134 (Tnc), in primary lung tumors and associated lymph node metastases compared with normal tissue.

135 tatic cells, such as miR23b, were reduced in lymph node metastases compared with patient-matched prim

136 as maintained and in many cases increased in lymph node metastases compared with primary tumors.

137 le used as a contrast agent for diagnosis of lymph-node metastases, compared with that of unenhanced

138 -FDG PET/CT and (18)F-FDG PET/MR imaging for lymph node metastases detection (P = 0.48).

139 eatment for a leg melanoma with duodenal and lymph nodes metastases developed a sudden bilateral visu

140 dies indicate a relatively high incidence of lymph node metastases, distant metastases, and persisten

141 les the direct PET visualization of sentinel lymph node metastases, eliminating the need for invasive

142 imaging has shown promise in helping detect lymph node metastases, even in small (subcentimeter) nod

143 node metastases and cell lines derived from lymph node metastases exhibited very similar patterns, p

144 aim of this study was to define the risk of lymph node metastases for intramucosal and submucosal (T

145 RI is sensitive and specific in detection of lymph-node metastases for various tumours.

146 gastric cancers of 113 patients and matched lymph node metastases from 61 of these patients.

147 hemical analyses of primary ESCC samples and lymph node metastases from a cohort of 160 patients who

148 flutamide or bicalutamide, or by excision of lymph node metastases from hormone-naive patients.

149 ul responses in patients with bulky regional lymph node metastases from penile cancer.

150 pendent patients as well as associating five lymph node metastases from the original patient set with

151 le to help differentiate even small melanoma lymph node metastases from the other lymphadenopathies (

152 underwent complete resection of stage IIIA (lymph node metastases >1 mm), IIIB, or IIIC cutaneous me

153 er and had complete resection of stage IIIA (lymph node metastases >1 mm), IIIB, or IIIC cutaneous me

154 It disappeared once more than 5 lymph node metastases had been cleared at other hospital

155 ment along major supplying vessels (proximal lymph node metastases) had a significantly higher rate o

156 sis that the presence and number of cervical lymph node metastases have an adverse impact on overall

157 [HR], 1.94; 95% CI, 1.11 to 3.39; P = .0209; lymph node metastases: HR, 3.63; 95% CI, 1.88 to 7.0; P

158 Sixty percent of individuals had regional lymph node metastases identified primarily in proximity

159 e (124)I-negative but (131)I-positive, and 2 lymph node metastases in 2 patients were (131)I-negative

160 ntification of 4 previously unknown lung and lymph node metastases in 2 patients.

161 ogeneous EGFR amplification in primary tumor/lymph node metastases in 4 of 14 cases, despite uniform

162 ximal duodenum, and associated with regional lymph node metastases in 60%.

163 (18)F-FDG PET/CT can identify lymph node metastases in a segment of patients with oral

164 ies will be needed to allow the detection of lymph node metastases in an individual patient.

165 tion of both tumor growth and development of lymph node metastases in both androgen-sensitive and and

166 The role of lymph node metastases in distant prostate cancer dissemi

167 or preoperatively evaluating the presence of lymph node metastases in endometrial carcinoma patients.

168 nd appears to be more sensitive in detecting lymph node metastases in lower lobe and hilar NSCLC comp

169 aging enables noninvasive detection of small lymph node metastases in normal-sized nodes in a substan

170 y reported as predictive for the presence of lymph node metastases in OSCC and OPSCC, was first re-ev

171 Risk of lymph node metastases in patients with pancreatic neuroe

172 The detection of occult lymph node metastases in patients with pT3N0 prostate ca

173 iously been used with great success to image lymph node metastases in prostate cancer patients.

174 The prevalence of lymph node metastases in SCC, AEG, and GC was 7%, 0%, an

175 nomogram predicting the likelihood of occult lymph node metastases in surgically resectable esophagea

176 Detection of lymph node metastases in the upper mediastinum and aroun

177 to have a clear understanding of the risk of lymph node metastases in these patients.

178 ependent tumor growth in vitro and increased lymph node metastases in vivo.

179 etection of small and otherwise undetectable lymph-node metastases in patients with prostate cancer.

180 Accurate detection of lymph-node metastases in prostate cancer is an essential

181 ted with somatic TP53 mutations and regional lymph-node metastases in sporadic breast cancer but not

182 Lymph node metastases, in contrast, display high levels

183 oxide (USPIO), may enhance the detection of lymph node metastases independent of node size.

184 tumor lineages seed distant metastases than lymph node metastases, indicating that the two sites are

185 colorectal cancers that was associated with lymph-node metastases (INHBB, AXL, FGFR1, and PDFGRB) an

186 Location of lymph node metastases is an independent predictor for su

187 Knowledge of the risk of lymph node metastases is critical to planning therapy fo

188 patients with recurrences to develop lung or lymph node metastases is eightfold (p = 0.056).

189 The detection of regional lymph node metastases is important in cancer staging as

190 Presence or absence of lymph node metastases is the most powerful predictor of

191 nectomy (LM/SL) for identification of occult lymph node metastases is well established in primary mel

192 he response rates were 63%, 88%, and 90% for lymph node metastases (LMs), pulmonary metastases, and T

193 on in thirds has shown an increasing rate of lymph node metastases (LNM) according to the depth of wa

194 Histopathological assessment of lymph node metastases (LNM) depends on subjective analys

195 DG PET/CT for the preoperative assessment of lymph node metastases (LNM) in endometrial cancer patien

196 th morphologic imaging for the assessment of lymph node metastases (LNM) in patients with recurrent p

197 Accurate detection of prostate cancer lymph node metastases (LNM) through PET/CT before lympha

198 Undetected lymph node metastases (LNMs) underwent immunohistochemic

199 tumor samples, covering the primary tumors, lymph node metastases (LNMs), and liver metastases from

200 investigated in human primary PCa (n = 90), lymph node metastases (LNMs; n = 8), and benign prostati

201 g T cell subsets was associated with skin or lymph node metastases, loss of CXCR4, CXCR5, and CCR9 co

202 By MVA, only lymph node metastases, major perioperative complications

203 itive primary tumors; it was not detected in lymph node metastases matched to BRAF mutation-negative

204 BRAF mutation was detected in 20 of 26 (77%) lymph node metastases matched to BRAF mutation-positive

205 Patients with axillary lymph node metastases may benefit from postmastectomy ra

206 e prediction of deep myometrial invasion and lymph node metastases may increase diagnostic accuracy a

207 Collectively, this comparison suggests that lymph node metastases may not be an intermediate develop

208 ) have a distinct MRI appearance compared to lymph node metastases (mrLNMs).

209 Polyclonal seeding was common in untreated lymph node metastases (n = 17 out of 29, 59%) and distan

210 Primary tumors (n = 43), local lymph node metastases (n = 74), and distant metastases (

211 64 months), we investigated the influence of lymph node metastases (N+), tumor infiltration depth, tu

212 criptomes (n=382), survival data (n=530) and lymph node metastases (n=100) in lung cancer patients id

213 Lateral pelvic lymph-node metastases occur in 10-25% of patients with r

214 es (P < 0.01) in vitro, as well as popliteal lymph node metastases of ESCC cells in nude mice (P = 0.

215 PLIN downregulation was also demonstrated in lymph node metastases of human solid tumors including PC

216 okinase-derived peptide (A6) in reducing the lymph node metastases of prostate cancer using a model i

217 The impact of these distant lymph node metastases on survival remains unclear.

218 ed to the mucosa, the reported prevalence of lymph node metastases once the tumor infiltrates the sub

219 e treated with a scrambled peptide developed lymph node metastases, only 22 to 25% of A6-treated mice

220 ded with time, in all 6 patients with either lymph node metastases or recurrent prostate bed carcinom

221 nce observer was low for number of organ and lymph node metastases (organ: ICC, 0.84; 95%CI, 0.77-0.8

222 d was found to be significantly decreased in lymph node metastases over paired primary tumors.

223 Lymph node metastases (P < 0.001), lymphovascular invasi

224 ted deep myometrial invasion (P < 0.015) and lymph node metastases (P < 0.025) after adjustment for p

225 Advanced T stage (P = .02), lymph node metastases (P = .004), and vascular space inv

226 nuclear level of DNAJB6 and the presence of lymph node metastases (P = .022; Pearson chi(2) test).

227 M6 expression was associated with absence of lymph node metastases (P = 0.012), lower disease stage (

228 ter methylation and the presence of regional lymph node metastases (P = 0.03).

229 = 0.0453) and borderline with the absence of lymph node metastases (p = 0.0571) and tumor proliferati

230 = 0.0238) and borderline with the absence of lymph node metastases (p = 0.0632).

231 the robust association of this profile with lymph node metastases (P = 7.3(-13)) and overall surviva

232 Conventional pathologic features (lymph node metastases, positive resection margin, poor g

233 Lymph node metastases, predominantly subtype-3, displaye

234 levels before reoperation and the number of lymph node metastases previously removed at outside faci

235 lymph node, presence or absence of sentinel lymph node metastases, primary tumor characteristics, di

236 emoval of 0 (r = 0.74 and 77%-0%) and 1 to 5 lymph node metastases (r = 0.61 and 60%-0%) elsewhere.

237 at PFKFB3 expression is highest in stage III lymph node metastases relative to normal breast tissues

238 f Syk expression were observed in tumors and lymph node metastases relative to normal tissues.

239 , which would have missed 51.9% and 74.1% of lymph node metastases, respectively.

240 ents) after previous removal of 0 and 1 to 5 lymph node metastases, respectively.

241 Risk estimation for lymph node metastases should not be based on depth of tu

242 Location of lymph node metastases should therefore be considered in

243 survival is lower for patients with regional lymph node metastases suggesting that a more systematic

244 tein E-cadherin was significant decreased in lymph node metastases, suggesting PRC2 promotes epitheli

245 With regional lymph node metastases, survival drops to 45-60%, and wit

246 ation and the previous removal of 5 or fewer lymph node metastases, systematic lymph node dissection

247 Lymph node metastases that occur frequently provide site

248 d tumor pairs in HNSCC, we found synchronous lymph node metastases to be genetically more similar to

249 ents with nonmetastatic CaP to patients with lymph node metastases to patients with skeletal metastas

250 r overall survival of patients with sentinel lymph node metastases treated with breast-conserving the

251 tudy population was limited to patients with lymph node metastases, tumors 4 cm or larger, or local e

252 ell as 41 normal prostate specimens and nine lymph node metastases, using cDNA microarrays containing

253 Sensitivity for detecting mediastinal lymph node metastases, using pathologic confirmation and

254 as significantly higher for patients without lymph node metastases versus those with lymph node metas

255 umor cell implantation were established from lymph node metastases via in vivo selection.

256 The presence of occult lymph node metastases was an independent predictor of re

257 The rate of axillary lymph node metastases was consistent with SLN tumor load

258 The prevalence of lymph node metastases was correlated with tumor size, de

259 The presence of lymph node metastases was determined by an experienced r

260 On multivariate analysis, location of lymph node metastases was independently associated with

261 tivariate analysis, the presence of regional lymph node metastases was the only factor associated wit

262 acy of (18)F-FDG PET/CT for the detection of lymph node metastases were 77%-85%, 91%-96%, and 89%-93%

263 r asymptomatic; without visceral disease but lymph node metastases were allowed).

264 Lymph node metastases were also significantly associated

265 that included p21 and pRB/p16, only p21 and lymph node metastases were associated with bladder cance

266 3 with p21 or p53 with pRB/p16, only p53 and lymph node metastases were associated with bladder cance

267 for predicting deep myometrial invasion and lymph node metastases were calculated.

268 Recently, it was questioned whether lymph node metastases were capable of metastasizing and

269 Occult lymph node metastases were categorized by pattern of sta

270 Lymph node metastases were detected in 37 patients (31%)

271 Analyzed according to hemipelvis, lymph node metastases were detected with histopathologic

272 Regional lymph node metastases were evident, and immunohistochemi

273 In SCC, lymph node metastases were found from the neck to the ce

274 Renal lymph node metastases were found in 15.8% of the animals

275 Eighty-eight lymph node metastases were found in 33 of 120 patients (

276 entification of deep myometrial invasion and lymph node metastases were generated, and MTV cutoffs fo

277 viewed, and the prevalence and topography of lymph node metastases were identified.

278 ents with PC at intermediate or high risk of lymph node metastases were included.

279 ortantly, although paired primary tumors and lymph node metastases were largely homogeneous for relev

280 On univariate analysis, high TRG and lymph node metastases were negatively related to surviva

281 Lymph node metastases were predicted using size criteria

282 Lymph node metastases were present in 10 axillary region

283 Results: Lymph node metastases were present in 18 patients (31.0%

284 Lymph node metastases were present in 19% of cases and 2

285 poradic groups (P = 0.95), respectively, and lymph node metastases were present in 43% and 30% of cas

286 Lymph node metastases were present in 68% (44% N1, 24% N

287 Lymph node metastases were present in the pelvis in 40.6

288 Lymph node metastases were present in the pelvis in 42%

289 Lymph node metastases were rare (1.3%) with intramucosal

290 ne metastasis, plotted against the number of lymph node metastases, were similar.

291 r lost in primary tumors and, in particular, lymph node metastases when compared with that in normal

292 rmed in cervical cancer patients with pelvic lymph node metastases, where we found v(0) to be higher

293 tatic adenocarcinoma with readily detectable lymph node metastases, whereas single models with each o

294 related with Gleason score and occurrence of lymph node metastases while little or no Runx2 phosphory

295 Patients with lymph node metastases who underwent 18F-FDG PET/CT > or

296 iews 75 T1a and 51 T1b tumors and correlates lymph node metastases with depth of tumor invasion, tumo

297 greatest efficacy in confirming celiac axis lymph node metastases with more than 90% accuracy.

298 the sensitivity of MRI in the prediction of lymph node metastases, with no loss of specificity.

299 ses, we recently found that TRAIL-R inhibits lymph node metastases without affecting primary tumor fo

300 ed CTGF-dependent tumor growth and inhibited lymph node metastases without any toxicity observed in n